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Zusammenfassung
Hintergrund: Die Rate lokaler Rezidive von kolorektalen
Karzinomen wurde durch die Einführung der kombinierten
Radiochemotherapie gesenkt. Trotz dieser Fortschritte ist
die Strategie bei der Therapie von lokal fortgeschrittenen
Rezidiven vorbehandelter Patienten problematisch und un-
gelöst. Patienten und Methoden: Wir analysierten retro-
spektiv die Daten zu Behandlung und Follow-up von 14 Pa-
tienten, die zwischen November 1997 und Dezember 2001
wegen Lokalrezidiven eines Rektumkarzinoms mit Bestrah-
lung (RT), Chemotherapie (CT) und Hyperthermie (RHT) be-
handelt wurden. Hiervon waren 9 Patienten mit Radioche-
motherapie vorbehandelt worden (vorbehandelte Patien-
ten). Diese Gruppe der vorbehandelten Patienten erhielt je-
weils 30,6–39,6 Gy RT und 5-Fluorouracil (5-FU) als
kontinuierliche Infusion 5 Tage pro Woche (350 mg/m2/24 h)
in Kombination mit RHT zweimal wöchentlich. Die 5 übri-
gen Patienten (nicht vorbehandelt) erhielten eine konforma-
le RT mit 45,0 Gy mit einer zusätzlichen Boost-RT zwischen
9,0 und 14,4 Gy in Kombination mit einer kontinuierlichen
Infusion von 5-FU an den Tagen 1–4 und 29–33 (500 mg/m2/
24 h) und RHT zweimal wöchentlich. Das Ansprechen auf
die Therapie wurde mittels Computertomographie (CT)
oder Magnetresonanztomographie (MRI) sowie klinischem
Follow-up evaluiert. Ergebnisse: Unter 13 auswertbaren Fäl-
len betrug die Ansprechrate 54% (5 vollständige Remissio-
nen, 2 partielle Remissionen). Nach einer mittleren Nachbe-
obachtungszeit von 13,9 Monaten (Bereich 5–32 Monate),
waren noch 7 Patienten am Leben. Schlussfolgerung: Das
beschriebene Therapieregime scheint bei Lokalrezidiven
von Rektumkarzinomen wirksam zu sein. Der wirksame
Anteil der Hyperthermie muss anhand von Studien mit grö-
ßeren Patietenzahlen überprüft werden.
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Summary
Background: The local recurrence rate of colorectal cancer
has been significantly reduced due to the use of combined
radiochemotherapy. Despite this improvement regarding
locally advanced tumour recurrences, the treatment strate-
gy for pre-treated patients remains difficult and unresolved.
Patients and Methods: We analysed treatment and follow-
up data of 14 patients with local recurrence of rectal cancer
who were treated with radiation therapy (RT), chemothera-
py (CT) and regional hyperthermia (RHT) from November
1997 to December 2001. Nine of these patients had received
irradiation and CT (= pre-treated patients) in the past. For
this group, 30.6–39.6 Gy RT, 5-fluorouracil (5-FU) as a con-
tinuous infusion over 5 days per week (350 mg/m2/24 h)
combined with RHT twice a week was given. The 5 remain-
ing patients (= not pre-treated) received conformal irradia-
tion of 45 Gy with a boost between 9 and 14.4 Gy, combined
with continuous infusion of 5-FU on days 1–4, and 29–33
(500 mg/m2/ 24 h), and RHT twice a week. Response to ther-
apy was evaluated by means of computed tomography (CT)
or magnetic resonance imaging (MRI) and by clinical fol-
low-up. Results: Among 13 evaluated cases, the overall ob-
jective response rate was 54% (5 complete responses, 2 par-
tial responses). At mean follow-up of 13.9 months (range
5–32 months) 7 patients were alive. Conclusion: The thera-
peutic regimen appears to be active in the treatment of local
recurrences of rectal cancer. Larger-scaled studies are need-
ed to evaluate the potency of hyperthermia in this therapeu-
tic strategy.
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Introduction
Colorectal cancer is one of the main cancer-related causes of
death. In Germany, the incidence of colorectal carcinoma
amounts to 55,000–60,000 cases per year, with a portion of
one third with localisation primarily in the rectum. Over the
past decades, significant progress has been made in develop-
ing effective adjuvant treatment regimens. Combined pre-op-
erative or post-operative therapy has significantly contributed
to improvement of local control and to survival of these pa-
tients [1–3]. The local recurrence rate has been dramatically
lowered through the use of radiotherapy (RT), especially in
combination with chemotherapy (CT). Modern radiation
techniques, such as conformal radiation, and new chemother-
apeutic regimens may have the potential to further increase
the therapeutic benefit. However, the treatment of inopera-
ble, advanced local tumour recurrences in patients who were
treated with surgery and radiochemotherapy (RCT) before,
remains a challenge to both the medical and the radiation on-
cologist. The aim of any treatment strategy for this cohort is
to increase local tumour control. At the same time, therapy-
related side-effects should be kept to a minimum as they can
dramatically reduce the patient’s quality of life. All effort’s
goal still remains to enable a curative resection of the tumour,
hence optimistic long-term perspectives can only be achieved
if a resection can be performed. 
Regional hyperthermia therapy (RHT) in combination with
RT or CT, yielded impressive results in phase-III studies
[4–6]. Profound research has produced a scientific basis for
the simultaneous application of hyperthermia in combination
with ionising irradiation and/or systemic CT [7]. Hyperther-
mia (HT) has become more widely accepted in the clinical
setting since substantial technical improvements have been
made to achieve selective temperature increases in both su-
perficial and more remote tumour locations [7]. The rationale
for the use of HT is based on the observations of (a) augmen-
tation of the potency of the used antineoplastic drugs, (b) en-
hancement of perfusion and oxygenation in the treated area,
and (c) direct cytotoxic effects of heat when tissue tempera-
tures are increased up to 44 °C. Synergistic effects of RHT
and RCT are well known [8]. In general, toxicity of HT is low.
HT is a useful adjunct to RT to enhance local control of ad-
vanced malignancies. The measured temperature distribution
in the tumour and in the immediately adjacent tissue is an im-
portant prognostic factor for the outcome [8]. 
A combined therapeutic regimen of HT and RT has been re-
ported to yield a higher clinical response rate and local con-
trol rate than RT alone [4–6]. Nevertheless, HT is still not
viewed as an established standard treatment modality in cases
of locally recurrent rectal cancer. The majority of patients
with local tumour recurrences were treated with both surgery
and RCT. Therefore, the options of local tumour treatment
are limited due to the cumulative effects of high dose irradia-
tion. Based on the published literature [4–6] and on our own
experience with RHT [7], we decided to combine the treat-
ment modalities of RHT and RCT with a limited irradiation
dose in order to enhance the local tumour control in patients
who had been irradiated in the past. In this article, we report
upon 14 patients treated with this regime and evaluated in ret-
rospective to determine the feasibility and morbidity of com-
bined external beam RT, continuous infusion of 5-fluorouracil
(5-FU), and external microwave HT.
Patients and Methods
This report is based on retrospective observation and evaluation of two
groups of patients affected by a locally recurrent rectal cancer: 
a. pre-treated patients who had already been treated with surgery and
RCT in the past (previously irradiated, PI-group); 
b. pre-treated patients with surgery alone (first-time irradiation, FI-
group). 
All patients had evidence of tumour recurrence as demonstrated by com-
puted tomography (CT) or magnetic resonance imaging (MRI), and all
were considered inoperable. 
From November 1997 to December 2001, 14 patients with locally recur-
rent rectal cancer were treated with a combination of RCT and RHT. All
patients had undergone attempts of curative surgical resections in the
past. Surgical resection had been followed by irradiation in 9 cases (PI-
group) with a total dose of 40–59.4 Gy and a fractionation of 1.8 Gy. Eight
of 9 patients had received a continuous infusion of 5-FU in the first and
the fifth week of irradiation. The 9th patient had been treated with 40 Gy
at the initial time of diagnosis at another hospital. All local recurrences in
the PI-group were considered inoperable at evaluation for feasibility.
Patients of the PI-group were treated with external beam irradiation
(conformal irradiation with a 4-fields technique) again, with 30.6 Gy (4
patients), 36 Gy (4 patients), and 39.6 Gy (1 patient), respectively. A frac-
tionation of 5 × 1.8 Gy was applied. The total cumulative doses ranged
from 84 Gy to 95.4 Gy. CT regimen consisted of a continuous infusion of
5-FU at a dose of 350 mg/m2/24 h for 5 days per week. This treatment reg-
imen was combined with HT twice a week. 
Dose finding in the PI-group was based on the following criteria: 
a. pre-irradiation dose, including time passed since the last irradiation; 
b. acute reaction during the current combined treatment. 
Of the 5 patients who had not been irradiated in the past (FI-group) 3
were treated with 54 Gy (45 Gy plus a 9 Gy boost), 1 patient was treated
with 59.4 Gy (45 Gy plus a 14.4 Gy boost), and 1 patient was treated with
45 Gy. Again, conformal irradiation was applied with a 4-fields technique.
Dose finding was based on the dose of post-operative irradiation applied
in this group. All patients were irradiated with 5 × 1.8 Gy/week with a
photon irradiation of 15 MV. CT regimen also included a continuous 5-
FU infusion at a dose of 500 mg/m2/24 h on days 1–4 and 29–33.
HT was applied twice a week during the period of RT for all patients one
hour after RT. HT was performed by using the annular phased array sys-
tem BSD-2000/3D (BSD Medical Corporation, Salt Lake City, UT) with
two types of applicators (Sigma-60 and Sigma-Eye, BSD Medical Corpo-
ration, Salt Lake City, UT). The Sigma-60 applicator is a 2D annular
phased array with a single ring of 8 dipole antennas. The Sigma Eye appli-
cator is an enhanced version of the Sigma-60 which provides 3D steering
using a triple ring of 24 dipole elliptical phased arrays with free phase se-
lection for every antenna pair. 
Therapy consisted of a plateau of 1-h HT-treatment after a temperature
of at least 42 °C had been achieved, or 30 min after initiation of the heat-
ing process. 
81 HT treatments were performed in 14 patients (mean 5.8 RHT per pa-
tient). In 11 of the 14 patients tumour-related temperature near the tu-
mour was measured via an endoluminally inserted catheter (rectal or
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vaginal). Endoluminal temperature measurement was not possible in the
remaining 3 male patients due to iatrogenic closure of the anal canal.
Temperature measuring catheters (Cook, Moenchengladbach, Germany)
with a measuring tract of 10–15 cm were routinely placed in the patient’s
rectum or vagina before initiation of HT and were subsequently removed
after each treatment session. 
Response to the treatment was evaluated by CT or MRI and by clinical
follow-up at the end of therapy and every 3 months thereafter. The re-
sponse was rated complete, if there was no evidence of recurrent tumour
on CT or MRI, and partial, if there was a tumour reduction of more than
50%. If a tumour volume reduction of less than 50% was observed, the
patient was rated to have no change. Morbidity and side-effects were
evaluated according to the common toxicity criteria (CTC) [9–10].
Results
From November 1997 to December 2001, 14 patients with re-
current rectal cancer were enrolled. Patient characteristics are
summarised in table 1. One patient from the FI-group had to
be excluded from the evaluation, since an R1 resection had
been performed before initiation of RCT and HT. Thus, re-
sponse was not possible.
Of the PI-group patients, 2 showed a complete remission,
while 1 had a partial remission. No change was observed in 5
patients, whereas 1 patient had progressive disease. In the FI-
group of patients with first-time RT, 3 showed a complete re-
mission, and one a partial remission.
For all observed patients, complete remission was observed in
38.5%, partial remission in 15.3%, no change in 38.5%, and
progression in 7.7%. Two patients of the FI-group subse-
quently underwent surgery with a curative intention – one pa-
tient with a radiographic complete remission had an R1 resec-
tion 4 weeks after conclusion of therapy, and 1 patient with a
radiographic partial remission underwent an R2 resection, al-
so 4 weeks after RCT + HT. Two patients from the PI-group
underwent a palliative resection after the treatment.
On the average, 5.8 sessions of HT were performed (range 1
to 10). One patient underwent only one session of HT due to
pronounced, uncontrollable pain during the treatment. Fifty-
five of 81 treatments were available for temperature analysis
of measurements of adjacent tissues by endoluminal catheters
(e.g. rectum, bladder, vagina). Average maximum tempera-
ture (Tmax) was 40.3 °C (range 39.6 to 41.1 °C) and the median
time-averaged temperatures achieved in 20%, 50% and 90%
of all measured tumour sites were 39.7 °C (T20) (range 39.1 to
40.4 °C), 39.3 °C (T50) (range 38.9 to 39.8 °C), and 38.8 °C
(T90) (range 38.4 to 39.2 °C), respectively.
Evaluating side-effects, no abscess, no sinus tract formation,
no delay of wound healing, no bleeding has been observed. A
subileus has been reported during the follow-up of 1 patient
as a late toxicity. Five patients suffered from a skin reaction, 1
rated grade I, 2 grade I–II, another was rated grade II–III and
yet another grade III. All patients suffering from skin reac-
tions higher than grade I, belonged to the PI-group. Diar-
rhoea grade II–III was observed in 2 patients (15.4%). During
HT, 5 patients complained about pain during the treatment.
As mentioned above, 1 patient declined to proceed with HT
after the first session. The other 4 patients received i.v. analge-
sia with opiates and proceeded with HT treatment regimen
without further constraints.
During the mean follow-up of 13.9 months (range 5–32
months), 7 patients showed no signs of local progression. Five
patients had signs of local progression during the observation
period, but were still alive at the time of this writing. Seven
patients died from distant metastases or local progression.
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Table 1. Patient characteristics
Patient Sex Month and year of Stage at the time of initial diagnosis Previous treatments Previous radiation Month and year of 
initial diagnosis dose (total), Gy local tumour 
recurrence
1 female 08/98 pT3+pT2M0G2Nx OP, RCT 54.0  09/00
2 female 01/94 pT2pN1M0G2 OP,RCT,HT,CT 40.0  10/00
3 female 06/95 pT2N0M0G2 OP, RCT 59.4  02/01
4 male 12/92 PT2N3G2M0 OP, RCT 50.0  03/01
5 female 04/91 pT3pN2M0G2–3 OP, RCT 50.0  07/00
6 male 01/96 pT3pN0M0G1–2 OP, RCT 50.4  07/01
7 female 07/96 pT1pN1M0G2 OP, RCT, CT 50.6  11/00
8 male 09/93 pT2pN0M0G2 OP, RCT, CT 54.0  08/00
9 female 01/00 pT3pN2M0G3R1 OP, RCT 45.0  11/00
10 male 03/89 pT3pN0M0G2 OP no 06/97
11 female 05/99 pT4pN0M0G2 OP no 09/99
12 male 05/00 pT3pN2M1(Liver)G2–3 OP, CT no 02/01
13 male 11/95 pT3pN3M1G2–3 OP no 08/01
14 male 01/96 pT3N0M0G2 OP no 12/98
OP = Surgery; RCT = radiation combined with chemotherapy; CT = chemotherapy.
Discussion
Local recurrences of colorectal cancer can be understood as
manifestations of disseminated disease spreading locoregion-
ally; synchronal distant metastases are often found in patients
with the diagnosis of a local recurrence and the probability of
cure or long-time survival is low [11]. However, survival
varies widely depending on tumour growth rate, which is de-
termined biologically but also influenced by surgery [11].
At present, there is no standard treatment regimen for locally
advanced recurrent rectal cancer. Treatment regimens for lo-
cally recurrent rectal cancer have significantly changed over
the past two decades with treatment goals shifting from pallia-
tion to possible cure. Various treatments methods have been
applied, such as RT combined with α-interferon [12], intra-
operative irradiation [13], re-irradiation by itself [14], or CT
[15]. However, if resection of the local tumour recurrence is
possible, it remains the most favoured and most promising cu-
rative approach. Attempts to find new chemotherapeutic
agents or radiosensitisers to enhance the local tumour control
are being pursued eagerly [16, 17]. The optimal point in time
for using CT in a multimodal regimen currently is under in-
vestigation. With modern radiation techniques such as 3D-
conformal irradiation, a relatively low rate of morbidity and a
low rate of toxicity can be achieved, even if pre-irradiation
was performed. The results of combining RCT with RHT
have been encouraging for a variety of tumour types [6–8, 18]. 
Combination of RHT with re-RCT appears to be useful in
treatment strategies for local tumour recurrences, and syner-
gistic effects may contribute to a better local control. The
mainstay of therapy remains RCT, however. Although it has
been shown that a combined treatment of rectal cancer with
RCT and RHT improved local control [4–6], the adverse ef-
fects of the combined therapy are defined insufficiently.
Our observations show a better local control in the group with
higher irradiation doses (3 complete and 1 partial remission),
while local control was less efficient in the group of patients
receiving a lower dose of (re-)irradiation. Thus, the major ef-
fect regarding local control may be connected to the dose of
irradiation. This observation goes with the findings of Ro-
mano et al. [18] who treated patients with locally advanced
rectal cancer with a combination of RT and RHT. In their
study the complete response rate was 32.5%, using radiation
with a total dose of 64 Gy. Due to the different irradiation
doses in our 2 groups, it is difficult to define an optimal dose.
Both, irradiation dose given before reoccurrence of tumour
and the acute side-effects during therapy, must be taken into
account. Based on our preliminary experience, we believe
that a radiation dose of 36–39.6 Gy (5 × 1.8 Gy) in previously
irradiated patients could be a compromise. In patients not ir-
radiated before, we consider the optimal dose to be 45 Gy
plus a 9–14.6 Gy boost. 
Survey of the distribution of temperatures achieved by HT is
crucial to maintain a constant quality. The rationale for using
an endoluminal temperature measurement was the previously
demonstrated correlation between the endoluminally mea-
sured temperature and the intratumoural temperature rises
[19]. Clinical experience shows that endoluminally measured
temperatures are generally 1–2 °C lower than the tempera-
ture measured within the tumour tissue. This explains the
moderately high average of maximum therapeutic tempera-
tures achieved in our patients. 
This therapeutic regimen was shown to be moderately toxic in
our patient groups in combination with HT and CT and no in-
terruption of therapy was necessary. A dermatitis grade III
was observed in 2 patients with re-irradiation who had re-
ceived a cumulative dose of 84–94.5 Gy. This can be attributed
to (a) a high cumulative irradiation dose and (b) the combina-
tion of RHT and RCT. Side-effects such as dermatitis and di-
arrhoea (toxicity grade III) have been mentioned by Anscher
et al. [5] in the treatment of recurrent rectal cancer with re-ir-
radiation and hyperthermia. 
In this analysis, follow-up time has been relatively short and
emphasis lay on feasibility, morbidity and toxicity of a com-
bined implementation of the described methods. The intro-
duction of a multimodal therapeutic regimen has been
demonstrated to have a clear-cut advantage over RT alone
[4–6, 18]. In concordance with previous data, the addition of
HT to the treatment regimen does not seem to enhance toxic-
ity or subacute morbidity [4–6, 18]. This combined therapeutic
regimen appears to be active against locally recurrent rectal
cancer warranting further consideration as a treatment option
for this population of suffering patients. 
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